Literature DB >> 18353956

Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein.

Wei Huang1, Jonathan Toma, Signe Fransen, Eric Stawiski, Jacqueline D Reeves, Jeannette M Whitcomb, Neil Parkin, Christos J Petropoulos.   

Abstract

Many studies have demonstrated that the third variable region (V3) of the human immunodeficiency virus type 1 (HIV-1) envelope protein (Env) is a major determinant of coreceptor tropism. Other regions in the surface gp120 subunit of Env can modulate coreceptor tropism in a manner that is not fully understood. In this study, we evaluated the effect of env determinants outside of V3 on coreceptor usage through the analysis of (i) patient-derived env clones that differ in coreceptor tropism, (ii) chimeric env sequences, and (iii) site-directed mutants. The introduction of distinct V3 sequences from CXCR4-using clones into an R5-tropic env backbone conferred the inefficient use of CXCR4 in some but not all cases. Conversely, in many cases, X4- and dual-tropic env backbones containing the V3 sequences of R5-tropic clones retained the ability to use CXCR4, suggesting that sequences outside of the V3 regions of these CXCR4-using clones were responsible for CXCR4 use. The determinants of CXCR4 use in a set of dual-tropic env sequences with V3 sequences identical to those of R5-tropic clones mapped to the gp41 transmembrane (TM) subunit. In one case, a single-amino-acid substitution in the fusion peptide of TM was able to confer CXCR4 use; however, TM substitutions associated with CXCR4 use varied among different env sequences. These results demonstrate that sequences in TM can modulate coreceptor specificity and that env sequences other than that of V3 may facilitate efficient CXCR4-mediated entry. We hypothesize that the latter plays an important role in the transition from CCR5 to CXCR4 coreceptor use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18353956      PMCID: PMC2395220          DOI: 10.1128/JVI.02676-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization.

Authors:  G Pollakis; S Kang; A Kliphuis; M I Chalaby; J Goudsmit; W A Paxton
Journal:  J Biol Chem       Date:  2001-01-16       Impact factor: 5.157

2.  Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein.

Authors:  Terri G Edwards; Stéphanie Wyss; Jacqueline D Reeves; Susan Zolla-Pazner; James A Hoxie; Robert W Doms; Frédéric Baribaud
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; X Wu; W A O'Brien; L Ratner; J C Kappes; G M Shaw; E Hunter
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

Authors:  B Labrosse; C Treboute; A Brelot; M Alizon
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Authors:  Jacqueline D Reeves; Stephen A Gallo; Navid Ahmad; John L Miamidian; Phoebe E Harvey; Matthew Sharron; Stefan Pohlmann; Jeffrey N Sfakianos; Cynthia A Derdeyn; Robert Blumenthal; Eric Hunter; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

6.  Conserved changes in envelope function during human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Rebecca Nedellec; Alejandra Ramos; Oliver Hartley; John L Miamidian; Jacqueline D Reeves; Donald E Mosier
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

7.  Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop.

Authors:  Noah G Hoffman; Francoise Seillier-Moiseiwitsch; JaeHyung Ahn; Jason M Walker; Ronald Swanstrom
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

8.  Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor.

Authors:  C A Derdeyn; J M Decker; J N Sfakianos; Z Zhang; W A O'Brien; L Ratner; G M Shaw; E Hunter
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

9.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

10.  Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.

Authors:  Mark A Jensen; Fu-Sheng Li; Angélique B van 't Wout; David C Nickle; Daniel Shriner; Hong-Xia He; Sherry McLaughlin; Raj Shankarappa; Joseph B Margolick; James I Mullins
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

View more
  45 in total

1.  Role for the terminal clasp of HIV-1 gp41 glycoprotein in the initiation of membrane fusion.

Authors:  Chan-Sien Lay; Louise E Ludlow; David Stapleton; Anna K Bellamy-McIntyre; Paul A Ramsland; Heidi E Drummer; Pantelis Poumbourios
Journal:  J Biol Chem       Date:  2011-10-05       Impact factor: 5.157

2.  Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection.

Authors:  Pierre Frange; Marie-Laure Chaix; Stéphanie Raymond; Julie Galimand; Christiane Deveau; Laurence Meyer; Cécile Goujard; Christine Rouzioux; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2010-08-04       Impact factor: 5.948

Review 3.  HIV-1 tropism.

Authors:  Aikichi Iwamoto; Noriaki Hosoya; Ai Kawana-Tachikawa
Journal:  Protein Cell       Date:  2010-07-07       Impact factor: 14.870

4.  Mutational pathways and genetic barriers to CXCR4-mediated entry by human immunodeficiency virus type 1.

Authors:  Wei Huang; Arne Frantzell; Jonathan Toma; Signe Fransen; Jeannette M Whitcomb; Eric Stawiski; Christos J Petropoulos
Journal:  Virology       Date:  2010-11-10       Impact factor: 3.616

5.  Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120.

Authors:  Jennifer L Kirchherr; Jennifer Hamilton; Xiaozhi Lu; S Gnanakaran; Mark Muldoon; Marcus Daniels; Webster Kasongo; Victor Chalwe; Chanda Mulenga; Lawrence Mwananyanda; Rosemary M Musonda; Xing Yuan; David C Montefiori; Bette T Korber; Barton F Haynes; Feng Gao
Journal:  Virology       Date:  2010-10-30       Impact factor: 3.616

Review 6.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

7.  Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS.

Authors:  Yoshiaki Nishimura; Masashi Shingai; Wendy R Lee; Reza Sadjadpour; Olivia K Donau; Ronald Willey; Jason M Brenchley; Ranjini Iyengar; Alicia Buckler-White; Tatsuhiko Igarashi; Malcolm A Martin
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

8.  Individuals with HIV-1 Subtype C Infection and Cryptococcal Meningitis Exhibit Viral Genetic Intermixing of HIV-1 Between Plasma and Cerebrospinal Fluid and a High Prevalence of CXCR4-Using Variants.

Authors:  Katlego Sojane; Richard T Kangethe; Christina C Chang; Mahomed-Yunus S Moosa; Sharon R Lewin; Martyn A French; Thumbi Ndung'u
Journal:  AIDS Res Hum Retroviruses       Date:  2018-05-23       Impact factor: 2.205

9.  HIV-1 subtype C envelope characteristics associated with divergent rates of chronic disease progression.

Authors:  Derseree Archary; Michelle L Gordon; Taryn N Green; Hoosen M Coovadia; Philip J R Goulder; Thumbi Ndung'u
Journal:  Retrovirology       Date:  2010-11-04       Impact factor: 4.602

10.  Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.

Authors:  Cleo G Anastassopoulou; Thomas J Ketas; Per Johan Klasse; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.